Effect of Nandrolone Decanoate on Serum Lipoprotein (a) and its isoforms in hemodialysis patients

Lipids in Health and Disease

Nadereh Rashtchizadeh¹  Mohammad Rohbaninoubar¹  Hassan Argani²  Amir Ghorbanihaghjo¹ 

[1] Department of Biochemistry, Drug Applied Research Center, Tabriz University of medical sciences, Tabriz, Iran;Hemodialysis and Nephrology Division of Emam Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

关键词: Nandrolone Decanoate – Hemodialysis – Lipoprotein(a);   

Others  :  1213290
DOI  :  10.1186/1476-511X-3-16

 received in 2004-04-21, accepted in 2004-06-29,  发布年份 2004

【 摘 要 】

Malnutrition, anemia and increased atherosclerosis are the main causes of mortality in hemodialysis patients. Therapies designed to improve the disorders might therefore be expected to improve outcome. The effects of Nandrolone Decanoate (ND), in 64 stable hemodialysis patients, were studied with respect to the following parameters: nutritional status, hematological indexes, lipid profiles including serum levels of lipoprotein(a) [Lp(a)] in terms of differences in apolipoprotein(a) [apo(a)]. The patients were treated with ND at dose of 100 mg/I.M./week for 4 months. After 2 and 4 months of treatment the elevations in the serum levels of albumin (p < 0.0001), creatinine (p < 0.009), hemoglobin (p < 0.03), hematocrit (p < 0.03), cholesterol (p = 0.007) and triglyceride (p < 0.04) were noticed. Marked decrease in the concentration of high-density lipoprotein cholesterol (p = 0.007) and Lp(a) (p < 0.0001) were also found. These effects after 2 months of treatment withdrawal were relatively constant. By dividing patients according to the baseline Lp(a) levels and molecular weight of apo(a) isoform, it was noticed that the decrease in serum Lp(a) was significant in patients with high Lp(a) (>30 mg/dl) than those of with low Lp(a) (<30 mg/dl), irrespective of apo(a) molecular weight. It may be suggested that, ND has beneficial effect on nutritional status and treatment of anemia in hemodialysis patients. In spite the adverse effect of ND on lipid profile, it decreases Lp(a) mostly in patients with high serum Lp(a) preferently by the effect on apo(a) gene transcriptional activity.

【 授权许可】

   
2004 Ghorbanihaghjo et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 6.

【 参考文献 】

• [1]Barton Pai A, Chretien C, Lau AH: The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002, 58:38-46.
• [2]Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999, 281:1275-1281.
• [3]Chan CT: Cardiovascular effects of frequent intensive hemodialysis. Semin Dial 2004, 17:99-103.
• [4]Teruel JL, Lasuncion MA, Rivera M, et al.: Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis 1997, 29:569-575.
• [5]Navarro JF, Mora-Fernandez C, Rivero A, et al.: Androgens for the treatment of anemia in peritoneal dialysis patients. Adv Perit Dial 1998, 14:232-235.
• [6]Teruel JL, Aguilera A, Marcen R, Navarro Antolin J, Garcia Otero G, Ortuno J: Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. Scand J Urol Nephrol 1996, 30:403-408.
• [7]Johnson CA: Use of androgens in patients with renal failure. Semin Dial 2000, 13:36-39.
• [8]Kronenberg F, Neyer U, Lhotta K, et al.: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999, 10:1027-1036.
• [9]Parsons DS, Reaveley DA, Pavitt DV, Misra M, Brown EA: Lipoprotein(a) levels in those with high molecular weight apo(a) isoforms may remain low in a significant proportion of patients with end-stage renal disease. Nephrol Dial Transplant 2003, 18:1848-1853.
• [10]Kronenberg F, Lingenhel A, Lhotta K, et al.: The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int 2004, 65:606-612.
• [11]Sechi LA, Zingaro L, Catena C, Perin A, De Marchi S, Bartoli E: Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int 1999, 56:1049-1057.
• [12]Cauza E, Kletzmaier J, Bodlaj G, Dunky A, Herrmann W, Kostner K: Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant 2003, 18:1568-1572.
• [13]Akaike M, Azuma H, Kagawa A, et al.: Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002, 48:1454-1459.
• [14]Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ: Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis 1996, 122:89-95.
• [15]Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH: Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-filed gel electrophoresis. J Clin Invest 1991, 87:2153-2161.
• [16]Kamboh MI, Ferrell RE, Kottke BA: Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 1991, 49:1063-1074.
• [17]MBewu AD, Durrington PN: Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990, 85:1-14.
• [18]Utermann G: The mysteries of lipoprotein(a). Science 1989, 246:904-910.
• [19]Klausen IC, Beisiegel U, Menzel HJ, Rosseneu M, Nicaud V, Faergeman O: Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1995, 15:1001-1008.
• [20]Linden T, Taddei-Peters W, Wilhelmsen L, et al.: Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 1998, 137:175-186.
• [21]Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J kidney Dis 1996, 27:1-25.
• [22]Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr: Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993, 91:443-447.
• [23]Tsai YH, Park S, Snook JT: Interaction among Lp(a) phenotypes, Lp(a) concentrations and lipoprotein response to fat-modified diets. J Nutr Biochem 1998, 9:106-113.
• [24]Gaubatz JW, Ghanem KI, Guevara J Jr, Nava ML, Patsch W, Morrisett JD: Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res 1990, 31:603-613.
• [25]Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC: Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis 1999, 33:1100-1106.
• [26]Kandoussi AM, Hugue V, Cachera C, et al.: Apo(a) phenotypes and Lp(a) concentrations in renal transplant patients. Nephron 1998, 80:183-187.
• [27]Rainwater DL: Lp(a) concentrations are related to plasma lipid concentrations. Atherosclerosis 1996, 127:13-18.
• [28]Nestel P, Noakes M, Belling B, et al.: Plasma lipoprotein lipid and Lp(a) changes with substitution of elaidic acid for oleic acid in the diet. J lipid Res 1992, 33:1029-1036.
• [29]Mensink RP, Zock PL, Katan MB, Hornstra G: Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans. J lipid Res 1992, 33:1493-1501.
• [30]Hunninghake DB, Stein EA, Mellies MJ: Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol 1993, 33:574-580.
• [31]Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L: Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 1988, 73:135-141.
• [32]Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P: Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 1995, 18:261-267.
• [33]Monte G, Mezdour H: The pharmacological effects of certain compounds on lipoprotein(a). Recenti Prog Med 1993, 84:855-863.
• [34]Navarro JF: In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrol Dial Transplant 2003, 18:2222-2226.
• [35]Teruel JL, Marcen R, Navarro JF, et al.: Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. Nephron 1995, 70:282-286.
• [36]Gonbert S, Malinsky S, Sposito AC, et al.: Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002, 164:305-311.
• [37]Scanu AM: Lp(a) lipoprotein-coping with heterogeneity. N Engl J Med 2003, 349:2089-2090.
• [38]Rader DJ, Cain W, Ikewaki K, et al.: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994, 93:2758-2763.
• [39]Brunner C, Lobentanz EM, Petho-Schramm A, et al.: The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996, 271:32403-32410.
• [40]Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J Kidney Dis 1996, 27:1-25.
• [41]Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr: Variation in lipoprotein(a) concentration among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993, 91:443-447.
• [42]Martin S, Ladona MG, Pedro-Botet J, Covas MI, Rubies-Prat J: Differential expression of double-band apolipoprotein(a) phenotypes in healthy Spanish subjects detected by SDS-agarose immunoblotting. Clin Chim Acta 1998, 277:191-205.